Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 57 recruiting now later-stage tilt #42 of 28,707 conditions

Coronary Artery Disease: later-stage trial registry

57 of 220 indexed Coronary Artery Disease trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #42 of 28,707 conditions by registered trial count.

220 US clinical trials · 57 currently recruiting · #42 of 28,707 conditions by registered trial count

Coronary Artery Disease: 220 US clinical trials tracked, 57 recruiting.

Coronary Artery Disease is the subject of 220 registered US clinical trials on ClinicalTrials.gov, 57 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is University of Florida, running 17 of these trials.

Enrollment posture brief

Registry condition coronary-artery-disease

OPEN 57 | RECR 26% | LATE 42 | EARLY 15 | RANK #42 | SPON 17

Nearest open-share peer: Adenocarcinoma (26% recruiting · 27 trials)

Autism Spectrum Disorder49.8%Mild Cognitive Impairment48.5%Sickle Cell Disease44.4%Coronary Artery Disease (thi…26%Diabetes Mellitus23.3%
Open-enrollment share among volume-matched conditions near Coronary Artery Disease

Coronary Artery Disease lists 57 open slots (26% of 220 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Coronary Artery Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Coronary Artery Disease is recruiting below its size-band peers.

    57 of 220 indexed trials (25.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Coronary Artery Disease trials is spread across many organizations.

    University of Florida accounts for 17 of 220 trials (7.7%). 134 distinct sponsors appear on at least one study for this condition label.

  3. Typical Coronary Artery Disease enrolment sits around 266 participants.

    Median target enrolment is 266 among the 220 trials that report a genuine target (sentinel values excluded). 70 of those (31.8%) plan for fewer than 100 participants.

  4. Coronary Artery Disease splits between interventional and observational designs.

    153 interventional and 67 observational studies make up this index (69.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 29Phase 317Phase 425

Open and recent trials

220 total, page 5 of 5

COMPLETED 40 participants

Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography

Paieon

NCT00973921

COMPLETED 34 participants

Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)

Cedars-Sinai Medical Center

NCT00892307

COMPLETED Phase 1 33 participants

Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

University of Louisville

NCT00474461

COMPLETED Phase 1 32 participants

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

AstraZeneca

NCT03400488

COMPLETED Phase 4 30 participants

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

Takeda

NCT01763996

COMPLETED 30 participants

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

National Human Genome Research Institute (NHGRI)

NCT01369953

COMPLETED Phase 4 30 participants

Peripheral Nerve Blocks for Above-the-knee Amputations

University of Florida

NCT03404180

COMPLETED Phase 1 21 participants

A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease

Fluoropharma

NCT00413647

COMPLETED NA 21 participants

PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR

Washington University School of Medicine

NCT05349084

COMPLETED Phase 4 20 participants

Reversing Ticagrelor's Effects With Fresh Platelets

Icahn School of Medicine at Mount Sinai

NCT02201394

COMPLETED 19 participants

Implementing Myocardial Computed Tomographic Perfusion in a Community Hospital Setting

Lancaster General Hospital

NCT02756234

COMPLETED 19 participants

Evaluation of MyoStrain™ in Clinical Practice

University of Kansas Medical Center

NCT03825224

COMPLETED 17 participants

Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor

University of Florida

NCT04668495

COMPLETED Phase 1 16 participants

Effect of Cocoa Flavanols on Vascular Function

University of California, San Francisco

NCT00553774

COMPLETED Phase 4 14 participants

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

University of Florida

NCT03489863

COMPLETED 13 participants

Prospective International Study of Coronary Subtraction Using 320 Detector Row CT (CorSub)

National Heart, Lung, and Blood Institute (NHLBI)

NCT02303067

COMPLETED NA 12 participants

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

Abbott Medical Devices

NCT02229864

COMPLETED NA 10 participants

Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis

University of North Carolina, Chapel Hill

NCT03169062

COMPLETED NA 9 participants

Assessment Of Vascular Health After Niacin Therapy (AVANT)

University of Pennsylvania

NCT02003638

COMPLETED NA 2 participants

Identification of Adverse Plaque Characteristics by Coronary MR Angiography

Cedars-Sinai Medical Center

NCT01986868

← Previous Page 5 of 5

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 9
Phase 3 17
Phase 4 25

Named interventions

Most-linked intervention names on Coronary Artery Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
7 trials
Ticagrelor Drug
4 trials
Placebo Other
4 trials
Colchicine Drug
3 trials
Clopidogrel Drug
3 trials
PROMUS Element Coronary Stent System Device
2 trials
Corus CAD (ASGES) Diagnostic test
2 trials
Percutaneous coronary intervention Device
2 trials

US sites by state

Facility locations filed on Coronary Artery Disease trials. A trial with sites in several states counts in each.

California 75 trials
New York 61 trials
Florida 58 trials
Georgia 40 trials
Massachusetts 36 trials
Minnesota 31 trials
Illinois 30 trials
Ohio 29 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Coronary Artery Disease page

220 registered trials, 57 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 57 Coronary Artery Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Florida sponsors the most Coronary Artery Disease trials on record, review their full trial history before evaluating a specific study. See University of Florida's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Artery Disease condition card totals 220 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.